Antwerp, Oct. 08, 2026 (GLOBE NEWSWIRE) -- ANTWERP, Belgium, 8 October 2026, 15:00 CET – CMB.TECH NV

Investment strengthens Bio-Techne's global GMP manufacturing infrastructure for cell therapy app

Investment strengthens Bio-Techne's global GMP manufacturing infrastructure for cell therapy applica

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Incyte (IN

(CSE: URAI / OTC: URAIF / FSE: 3QG0) investor@inturai.com DomeCommand, the drone command-and-control

Shares of Bio-Techne Corp (NASDAQ: TECH - Get Free Report) hit a new 52-week high on Monday. The com

KEY HIGHLIGHTS Strategic Acquisition: Zhibao Technology Inc. (NASDAQ: ZBAO) ("Zhibao," "we," or the

Bio-Techne Corporation (NASDAQ:TECH) ("Bio-Techne"), a global provider of life science tools

MINNEAPOLIS, Sept. 23, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) ("Bio-Techne"), a

New flagship facility provides hands-on access to Bio-Techne technologies, workflows and scientific

Techne (TECH) reported earnings 30 days ago. What's next for the stock?

$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Looming Merger Shareholder Vote - AUUD

CMB.TECH delivered a 134% return in under a year, driven by a strategic dry bulk focus and strong ta

BALA CYNWYD, Pa., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the follow

ANTWERP, Belgium, 8 September 2026, 08:00 a.m. CET – CMB.TECH NV (NYSE: CMBT & Euronext: CMBT) (“CMB

Fiscal 2026 highlights:Science Based Targets initiative validates Bio-Techne's Scope 1, 2 and 3

Fiscal 2026 highlights: Science Based Targets initiative validates Bio-Techne's Scope 1, 2 and 3 gre

CMB.TECH (CMBT) shows improved earnings quality as core shipping EBITDA rises despite reduced ship s

CMB.TECH NV (CMBT) Q2 2026 Earnings Call Transcript

CMB.TECH NYSE: CMBT reported second-quarter 2026 net profit of $364.4 million, supported by revenue

ANTWERP, Belgium, 27 August 2026 – CMB.TECH NV (“CMBT”, “CMB.TECH” or “the company”) (NYSE: CMBT, Eu

BALA CYNWYD, Pa., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the followi

Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Bio-Techne Corporation (

Wells Fargo analyst Brandon Couillard downgrades Bio-Techne (NASDAQ:TECH) from Overweight to Equa

Bio-Techne (NASDAQ:TECH) reported quarterly earnings of $0.52 per share which met the analyst consen

Private equity giants circle Qiagen (QGEN) with potential bids of $50/share. Get the details on the

RBC Capital analyst Dan Leonard downgrades Bio-Techne (NASDAQ:TECH) from Outperform to Sector Per

TD Cowen analyst Kyle Boucher downgrades Bio-Techne (NASDAQ:TECH) from Buy to Hold and raises the

Citigroup analyst Patrick Donnelly downgrades Bio-Techne (NASDAQ:TECH) from Buy to Neutral and ra

Stephens & Co. analyst Steven Etoch downgrades Bio-Techne (NASDAQ:TECH) from Overweight to Eq

Baird analyst Catherine Schulte maintains Bio-Techne (NASDAQ:TECH) with a Neutral and raises the

Termination Fees The Company will be required to pay to Parent a termination fee equal to $230,455,0

Micron's blowout earnings powered memory and chip stocks higher, but the broad stock market rall

Gainers Atlantic International (NASDAQ:ATLN) shares increased by 41.0% to $1.1 during Thursday'

Dow Jones index gained 200 points; Acuity Inc (NYSE: AYI) reported better-than-expected financial re

Merck KGaA is acquiring Bio-Techne in an $11.3B all-cash deal to expand its life science, diagnostic

Gainers Adicet Bio (NASDAQ:ACET) stock moved upwards by 22.9% to $10.14 during Thursday's pre-m

Merck KGaA, Darmstadt, Germany, a leading science and technology company, and Bio-Techne Corporation

https://www.bloomberg.com/news/articles/2026-06-15/activist-investor-ananym-urges-bio-techne-to-cons

Piper Sandler analyst David Westenberg initiates coverage on Bio-Techne (NASDAQ:TECH) with a Neut

By combining R&D Systems MauriceFlex™ imaged capillary isoelectric focusing (icIEF) fractionatio

RBC Capital analyst Dan Leonard reinstates Bio-Techne (NASDAQ:TECH) with a Outperform and announc

Citigroup analyst Patrick Donnelly maintains Bio-Techne (NASDAQ:TECH) with a Buy and lowers the p

Wells Fargo analyst Brandon Couillard maintains Bio-Techne (NASDAQ:TECH) with a Overweight and lo

Evercore ISI Group analyst Daniel Markowitz maintains Bio-Techne (NASDAQ:TECH) with a In-Line and

U.S. stocks hit records as Trump's Iran memo sinks oil 6%, AMD soars 17% on data-center beat.

Bio-Techne (NASDAQ:TECH) reported quarterly earnings of $0.53 per share which missed the analyst con

Evercore ISI Group analyst Daniel Markowitz maintains Bio-Techne (NASDAQ:TECH) with a In-Line and